{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35","value":"159000"}]}],"title":"Pemetrexed, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35","value":"160000"}]}],"title":"Pemetrexed, AUC (0-∞)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"163000"}]}],"title":"T-platinum from cisplatin, AUC (0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"269000"}]}],"title":"T-platinum from cisplatin, AUC (0-∞)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"AUC(0-tlast) and AUC(0-∞) values are reported for pemetrexed and t-platinum from cisplatin. The number of pharmacokinetic observations (n) used in the analysis is presented for each drug.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cycles 1-2 (21-day cycle):\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nDay 2: LY2603618 130 to 275 mg\n\nAfter 2 cycles, participants may have continued on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nPemetrexed, cisplatin, and LY2603618 were administered IV over 10 minutes, 1 hour, and 1 hour, respectively.","id":"OG000","title":"Phase 1: Pemetrexed + Cisplatin + LY2603618"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Phase 1 participants who received at least 1 dose of pemetrexed or cisplatin and had samples collected for pharmacokinetic analysis.","reportingStatus":"POSTED","timeFrame":"Pemetrexed: Cycle 1/Day 1 - immediately prior to end of pemetrexed infusion and 1, 2, 6 and 24 hours postdose. Cisplatin: Cycle 1/Day 1 - immediately prior to end of cisplatin infusion and 0.5, 1, 2, 6, 24, 72, 96, and 168 hours postdose.","title":"Phase 1: Pharmacokinetic: AUC (Pemetrexed and Cisplatin)","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}